pyrroles has been researched along with Fatigue in 62 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 10 (16.13) | 29.6817 |
| 2010's | 49 (79.03) | 24.3611 |
| 2020's | 3 (4.84) | 2.80 |
| Authors | Studies |
|---|---|
| Bartlett, SJ; Bingham, CO; Cella, D; Gold, DA; Gruben, D; Murray, C; van Vollenhoven, R | 1 |
| Cappelleri, JC; Dina, O; Fallon, L; Fleishaker, D; Magrey, M; Navarro-Compán, V; Strand, V; Van den Bosch, F; Wang, C; Wang, L; Wei, JC; Wu, J | 1 |
| Bender, S; Boix, O; Cassier, PA; Cathomas, R; Cho, BC; Ellinghaus, P; Gajate, P; Grevel, J; Joerger, M; Navarro, A; Nogai, H; Nogova, L; Ocker, M; Park, SH; Penel, N; Rajagopalan, P; Richly, H; Sayehli, CM; Schostak, M; Schuler, M; Soo, RA; Tai, D | 1 |
| Choy, EH | 1 |
| Alten, R; Diehl, A; Germino, R; Kaine, J; Murray, CW; Shi, H; Strand, V; Wallenstein, G | 1 |
| Blackwood, EM; Cousin, S; DuPree, K; Epler, J; Hamilton, E; Hollebecque, A; Infante, JR; Italiano, A; Lauchle, JO; LoRusso, PM; Lu, X; Mahrus, S; Moein, A; Moore, KN; Murray, ER; Peale, FV; Postel-Vinay, S; Schutzman, JL; Shapiro, GI; Soria, JC; Tagen, M; Tolaney, S; Toulmonde, M | 1 |
| Aki, R; Ito, T; Matsushita, Y; Miyake, H; Motoyama, D; Otsuka, A; Sugiyama, T; Tamura, K | 1 |
| Adashek, JJ; Bergerot, PG; Boyd, T; Carret, AS; Chhabra, S; Forero-Torres, A; Gartner, EM; Hoimes, CJ; Li, H; Morris, JC; Pal, SK; Smith, DC; Thompson, JA; Vogelzang, NJ; Yu, X | 1 |
| Cataruozolo, PE; Cesari, R; Collier, M; Cortés, J; Curigliano, G; Elias, A; Goldhirsch, A; Huang, X; Kern, KA; Khosravan, R; Pivot, X | 1 |
| A, M; H J, H; L, M; M, K; N, M; P J, G; S, B | 1 |
| Bahl, A; Castellano, D; Chen, I; Chow Maneval, E; Daugaard, G; Gschwend, J; Houede, N; Jones, R; Laestadius, F; Lechuga, MJ; Maurina, T; Michaelson, MD; Ostler, P; Ou, YC; Oudard, S; Paolini, J; Saad, F; Sengeløv, L; Stenzl, A; Ullèn, A; Wang, SL | 1 |
| Arnaldi, G; Cascinu, S; Conti, A; De Giorgi, U; Iacovelli, R; Massari, F; Procopio, G; Rizzo, M; Santoni, M; Tortora, G; Trementino, L | 1 |
| Amato, AA; Puig, A; Scripko, PD | 1 |
| Dreicer, R; Elson, P; Garcia, JA; Mittal, K; Najjar, YG; Rini, BI; Wood, L | 1 |
| Battista, K; Buckstein, R; Howson-Jan, K; Ivy, SP; Kovacs, MJ; Oza, AM; Schuh, AC; Storring, JM; Wang, ES; Wang, L; Wells, RA; Xenocostas, A; Yee, KW | 1 |
| Bushmakin, AG; Cappelleri, JC; Cella, D; Charbonneau, C; Davis, MP; Figlin, RA; Korytowsky, B; Matczak, E; Michaelson, MD; Motzer, RJ; Négrier, S; Sandin, R | 1 |
| Beijnen, JH; Cirkel, GA; de Jonge, MJ; Gadellaa-van Hooijdonk, CG; Haanen, JB; Huitema, AD; Kloth, JS; Lankheet, NA; Lolkema, MP; Mathijssen, RH; Schellens, JH; Sleijfer, S; Steeghs, N; Voest, EE | 1 |
| Beaumont, JL; Bhattacharyya, H; Cella, D; Hahn, EA; Jensen, SE; Korytowsky, B; Motzer, R | 1 |
| Faivre, S; Grande, E; Hubner, RA; Raymond, E; Valle, JW | 1 |
| Biasco, G; Chen, L; Demetri, GD; Fly, K; Fumagalli, E; Gelderblom, H; Hurwitz, HI; Kaiser, PE; Kang, YK; Lechuga, MJ; Matczak, E; Reichardt, P; Rosen, LS; Rutkowski, P; Schuette, J; Seddon, B; Williams, CC; Yalcin, S | 1 |
| Charles, LP; DeAnnuntis, L; Escudier, B; Gore, ME; Hariharan, S; Motzer, RJ; Porta, C; Rini, BI; Yang, L | 1 |
| Bjarnason, GA; Cohen, DP; Davis, MP; Donskov, F; Goldstein, D; Lin, X; Michaelson, MD; Motzer, RJ; Puzanov, I; Rini, BI; Wiltshire, R | 1 |
| Albiges, L; Choueiri, TK; De Velasco, G; Fay, AP; Heng, DY; Kaymakcalan, MD; Kollmannsberger, CK; Kroeger, N; Lee, JL; McKay, RR; North, SA; Rha, SY; Smoragiewicz, M; Wells, JC; Xie, W | 1 |
| Barett, C; Bikas, A; Burman, KD; Clark, BG; Desale, S; Gandhi, R; Jelinek, JS; Kundra, P; Mete, M; O'Keefe, K; Wartofsky, L; Wexler, JA; Wray, L | 1 |
| Alexandre, J; Arrondeau, J; Blanchet, B; Boudou-Rouquette, P; Bretagne, M; Cabanes, L; Cessot, A; Chahwakilian, A; Coriat, R; Goldwasser, F; Huillard, O; Orvoen, G; Thomas-Schoemann, A; Tlemsani, C | 1 |
| Chi, Z; Cui, C; Guo, J; Li, S; Lian, B; Mao, L; Sheng, X; Si, L; Tang, B; Wang, X; Yan, X | 1 |
| Blumenstengel, K; Busies, S; Hutzschenreuter, U; Marschner, N; Müller, L; Münch, A | 1 |
| Keck, B; Lieb, V; Lüdecke, G; Sikic, D | 1 |
| Aziz, SA; Bhat, GM; Changal, KH; Lone, AR; Mir, MH | 1 |
| Choi, HY; Chung, J; Jeon, SH; Kim, SH; Kim, WJ; Kim, YJ; Kwon, TG; Lee, HL; Lee, HM; Seo, SI | 1 |
| DeMasi, R; Kwok, K; Nduaka, C; Schulze-Koops, H; Strand, V; Wallenstein, G; Wang, L | 1 |
| Baggstrom, MQ; Baker, S; Crawford, JA; Edelman, MJ; Feliciano, J; Gu, L; Hahn, O; Novotny, P; Socinski, MA; Stinchcombe, TE; Vokes, EE; Wang, XF | 1 |
| Fayyad, R; Figlin, RA; Hariharan, S; Hudes, G; Kempin, S; Motzer, RJ; Schwartz, LH; Wilding, G | 1 |
| Andreiuolo, F; Bobos, M; Calderaro, J; Fountzilas, G; Fragkoulidi, A; Kalogera-Fountzila, A; Marselos, M; Nikolaidou, M | 1 |
| Wood, LS | 1 |
| Bello, CL; Demetri, GD; Houk, BE; Motzer, RJ; Poland, B; Rosen, LS | 1 |
| Ahn, H; Ahn, JH; Hong, B; Hong, JH; Kim, CS; Kim, JE; Lee, DH; Lee, JL; Lee, JS; Na, S; Song, C; Yoo, C | 1 |
| Grünwald, V; Kalanovic, D; Merseburger, AS | 1 |
| Arnold, D; Ravaud, A; Schmidinger, M; Szczylik, C; Wagstaff, J | 1 |
| Bello, A; Burris, HA; Chao, R; Chiorean, EG; Jones, S; Lee, FC; Liau, KF; Royce, M; Sweeney, CJ; Tye, L; Verschraegen, CF | 1 |
| Hara, K; Hijioka, S; Kawai, H; Kondo, S; Matsumoto, K; Mizuno, N; Niwa, Y; Sawaki, A; Tajika, M; Yamao, K | 1 |
| Berlin, JD; Calcutt, MW; Chen, AP; Hachey, DL; Hartley, JA; Lee, W; Liao, CY; Puzanov, I; Rothenberg, ML; Spanswick, VJ; Vermeulen, WL | 1 |
| Canipari, C; Chen, K; Duh, MS; Imarisio, I; Neary, M; Paglino, C; Porta, C | 1 |
| Bjarnason, G; Bukowski, R; Burnett, P; Creel, P; Davis, M; Dawson, N; Feldman, D; George, S; Hershman, J; Kollmannsberger, C; Lechner, T; Potter, A; Raymond, E; Treister, N; Wood, L; Wu, S | 1 |
| Antón-Aparicio, LM; Cassinello, J; Castellano, D; Esteban, E; González-Larriba, JL; Grande, E; Sepúlveda, J | 1 |
| Joly, F | 1 |
| Ahn, H; Ahn, JH; Ahn, S; Ahn, Y; Hong, JH; Kim, CS; Kim, TW; Lee, JL; Park, I; Park, K; Park, S; Song, C | 1 |
| Camidge, DR; Chan, E; Chow Maneval, E; Diab, S; Eckhardt, SG; Khosravan, R; Leong, S; Lin, X; Lockhart, AC; Messersmith, WA; Spratlin, J | 1 |
| He, H; Shen, Z; Wang, H; Wang, X; Wu, Y; Zhang, C; Zhao, J; Zhou, W; Zhu, Y | 1 |
| Baba, S; Fujita, T; Ishii, D; Iwamura, M; Matsumoto, K; Tabata, K; Yoshida, K | 1 |
| Brickman, MJ; Citrin, DL; Dees, EC; Healey, P; Kern, KA; Li, S; Myers, SD; Paolini, J; Wang, Z; Yardley, DA | 1 |
| Bregant, C; Ganini, C; Imarisio, I; Morbini, P; Paglino, C; Porta, C; Vercelli, A | 1 |
| Kalonia, H; Kumar, A; Kumar, P; Mishra, J; Vashist, A | 1 |
| Bondarenko, I; Carrato, A; Christensen, JG; De la Cruz, JA; Jonker, DJ; Korytowsky, B; Lechuga, MJ; Lim, R; Lin, X; Roman, L; Shparyk, Y; Staszewska-Skurczynska, M; Sun, Y; Swieboda-Sadlej, A; Tursi, JM; Van Cutsem, E; Williams, JA | 1 |
| Cropp, G; Gosalia, R; Hannah, A; Sheldon, M; Stopeck, A; Vahedian, M | 1 |
| Fischbach, PS; Rice, KC; Savit, AZ; Verhoeven, RE; Wood, SK; Woods, JH | 1 |
| Senior, K | 1 |
| Dumez, H; Schöffski, P; Wolter, P | 1 |
| Baum, C; Bello, CL; Britten, CD; Hecht, JR; Kabbinavar, F; Li, J; Slamon, D | 1 |
| Atkins, JN; Belani, CP; Brahmer, JR; Chao, RC; Gillenwater, HH; Govindan, R; Novello, S; Pallares, C; Rosell, R; Sanchez, JM; Scagliotti, GV; Selaru, P; Socinski, MA; Tye, L | 1 |
| Konijnenberg, A; Megens, MP; Willems, PM | 1 |
| Adams, BJ; Baum, CM; Bello, CL; Burstein, HJ; Cobleigh, MA; DePrimo, SE; Eisenberg, PD; Elias, AD; Lehman, M; Miller, KD; Rugo, HS; Wolff, AC | 1 |
9 review(s) available for pyrroles and Fatigue
| Article | Year |
|---|---|
Effect of biologics and targeted synthetic disease-modifying anti-rheumatic drugs on fatigue in rheumatoid arthritis.
Topics: Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Azetidines; Biological Products; Fatigue; Humans; Piperidines; Purines; Pyrazoles; Pyrimidines; Pyrroles; Sulfonamides | 2019 |
Treatment-related fatigue with sorafenib, sunitinib and pazopanib in patients with advanced solid tumors: an up-to-date review and meta-analysis of clinical trials.
Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; Fatigue; Humans; Incidence; Indazoles; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Risk; Sorafenib; Sulfonamides; Sunitinib | 2015 |
[Tyrosine kinase inhibiting the VEGF pathway and elderly people: Tolerance, pre-treatment assessment and side effects management].
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Axitinib; Fatigue; Humans; Imidazoles; Indazoles; Indoles; Kidney; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib | 2016 |
[Side effect management of tyrosine kinase inhibitors in urology : Fatigue and hypothyroidism].
Topics: Anilides; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Disease Progression; Enzyme Inhibitors; Fatigue; Humans; Hypothyroidism; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quality of Life; Sorafenib; Sulfonamides; Sunitinib | 2016 |
Management of vascular endothelial growth factor and multikinase inhibitor side effects.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Diarrhea; Drug Eruptions; Drug Monitoring; Fatigue; Humans; Indoles; Interleukin-2; Intracellular Signaling Peptides and Proteins; Kidney Neoplasms; Male; Niacinamide; Oncology Nursing; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyridines; Pyrroles; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2009 |
Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis.
Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Blood Pressure; Carcinoma, Renal Cell; Endpoint Determination; Fatigue; Female; Gastrointestinal Stromal Tumors; Humans; Indoles; Kidney Neoplasms; Leukocyte Count; Linear Models; Male; Middle Aged; Neoplasms; Neutrophils; Nonlinear Dynamics; Population; Pyrroles; Sunitinib | 2010 |
Management of sunitinib-related adverse events: an evidence- and expert-based consensus approach.
Topics: Carcinoma, Renal Cell; Consensus; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Early Detection of Cancer; Evidence-Based Medicine; Fatigue; Female; Follow-Up Studies; Humans; Hypertension; Indoles; Kidney Neoplasms; Male; Mouth Diseases; Practice Guidelines as Topic; Protein Kinase Inhibitors; Pyrroles; Risk Assessment; Skin Diseases; Sunitinib; Treatment Outcome | 2010 |
Sunitinib in metastatic renal cell carcinoma: recommendations for management of noncardiovascular toxicities.
Topics: Asthenia; Carcinoma, Renal Cell; Diarrhea; Dose-Response Relationship, Drug; Erythema; Exanthema; Fatigue; Humans; Hypothyroidism; Indoles; Kidney Neoplasms; Practice Guidelines as Topic; Protein Kinase Inhibitors; Pyrroles; Standard of Care; Sunitinib | 2011 |
[Renal carcinoma and fatigue: which challenge in the era of antiangiogenic drugs?].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Fatigue; Humans; Indazoles; Indoles; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Sorafenib; Sulfonamides; Sunitinib | 2011 |
32 trial(s) available for pyrroles and Fatigue
| Article | Year |
|---|---|
The impact of tofacitinib on fatigue, sleep, and health-related quality of life in patients with rheumatoid arthritis: a post hoc analysis of data from Phase 3 trials.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Fatigue; Humans; Methotrexate; Piperidines; Pyrimidines; Pyrroles; Quality of Life; Sleep; Treatment Outcome | 2022 |
Effect of tofacitinib on pain, fatigue, health-related quality of life and work productivity in patients with active ankylosing spondylitis: results from a phase III, randomised, double-blind, placebo-controlled trial.
Topics: Adult; Antirheumatic Agents; Fatigue; Humans; Pain; Piperidines; Pyrimidines; Pyrroles; Quality of Life; Spondylitis, Ankylosing; Treatment Outcome | 2022 |
Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study.
Topics: Acute Kidney Injury; Aged; Anorexia; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Diarrhea; Fatigue; Female; Humans; Hyperphosphatemia; Hypoglycemia; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Piperazines; Pyrroles; Receptor, Fibroblast Growth Factor, Type 1; Receptor, Fibroblast Growth Factor, Type 2; Receptor, Fibroblast Growth Factor, Type 3; Receptors, Fibroblast Growth Factor; RNA, Messenger; Squamous Cell Carcinoma of Head and Neck; Thiophenes; Vomiting | 2019 |
Associations between Patient Global Assessment scores and pain, physical function, and fatigue in rheumatoid arthritis: a post hoc analysis of data from phase 3 trials of tofacitinib.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Fatigue; Humans; Pain; Piperidines; Pyrimidines; Pyrroles; Treatment Outcome | 2020 |
Phase I study of the checkpoint kinase 1 inhibitor GDC-0575 in combination with gemcitabine in patients with refractory solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Checkpoint Kinase 1; Deoxycytidine; Dose-Response Relationship, Drug; Drug Interactions; Fatigue; Female; Gemcitabine; Half-Life; Humans; Male; Maximum Tolerated Dose; Middle Aged; Nausea; Neoplasms; Neutropenia; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrroles; Thrombocytopenia; Treatment Outcome | 2018 |
A phase 1 trial of SGN-CD70A in patients with CD70-positive, metastatic renal cell carcinoma.
Topics: Aged; Anemia; Benzodiazepines; Carcinoma, Renal Cell; CD27 Ligand; Edema; Fatigue; Female; Humans; Immunoconjugates; Kidney Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Pyrroles; Thrombocytopenia | 2019 |
Randomized phase II study of sunitinib versus standard of care for patients with previously treated advanced triple-negative breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Docetaxel; Fatigue; Female; Fluorouracil; Gemcitabine; Hand-Foot Syndrome; Humans; Indoles; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Pyrroles; Sunitinib; Survival Rate; Taxoids; Thrombocytopenia; Triple Negative Breast Neoplasms | 2013 |
A cross-sectional investigation of fatigue in advanced renal cell carcinoma treatment: results from the FAMOUS study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Renal Cell; Cross-Sectional Studies; Everolimus; Fatigue; Female; Humans; Incidence; Indoles; Interferon-alpha; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Physicians; Pyrroles; Quality of Life; Self Report; Sirolimus; Sorafenib; Sunitinib; Surveys and Questionnaires | 2014 |
Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Disease Progression; Disease-Free Survival; Docetaxel; Double-Blind Method; Drug Administration Schedule; Drug Resistance, Neoplasm; Fatigue; Humans; Indoles; Kaplan-Meier Estimate; Lymphopenia; Male; Middle Aged; Neoplasm Metastasis; Orchiectomy; Prednisone; Prostatic Neoplasms; Pyrroles; Sunitinib; Taxoids; Treatment Outcome | 2014 |
Sunitinib malate in patients with intermediate-2 or high-risk myelodysplastic syndrome or chronic myelomonocytic leukemia.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Diarrhea; Drug Administration Schedule; Fatigue; Female; Humans; Indoles; Kaplan-Meier Estimate; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Pyrroles; Remission Induction; Sunitinib; Thrombocytopenia; Treatment Outcome | 2014 |
Characterizing fatigue associated with sunitinib and its impact on health-related quality of life in patients with metastatic renal cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Drug Administration Schedule; Fatigue; Female; Humans; Indoles; Interferon-alpha; Kidney Neoplasms; Male; Models, Statistical; Neoplasm Metastasis; Pyrroles; Quality of Life; Retrospective Studies; Sunitinib; Surveys and Questionnaires; Treatment Outcome | 2014 |
Pharmacokinetically guided sunitinib dosing: a feasibility study in patients with advanced solid tumours.
Topics: Adult; Aged; Antineoplastic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Monitoring; Fatigue; Feasibility Studies; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Indoles; Male; Middle Aged; Neoplasms; Nervous System Diseases; Pilot Projects; Protein Kinase Inhibitors; Pyrroles; Salvage Therapy; Sunitinib | 2014 |
Clinical outcomes of patients with advanced gastrointestinal stromal tumors: safety and efficacy in a worldwide treatment-use trial of sunitinib.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Child; Diarrhea; Disease-Free Survival; Fatigue; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Indoles; Kaplan-Meier Estimate; Male; Middle Aged; Proportional Hazards Models; Pyrroles; Sarcoma; Sunitinib; Treatment Outcome; Young Adult | 2015 |
Phase 2 clinical trial of sunitinib as adjunctive treatment in patients with advanced differentiated thyroid cancer.
Topics: Adenocarcinoma, Follicular; Adenoma, Oxyphilic; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; Carcinoma; Carcinoma, Papillary; Chemotherapy, Adjuvant; Diarrhea; Disease-Free Survival; Fatigue; Female; Hand-Foot Syndrome; Humans; Indoles; Iodine Radioisotopes; Leukopenia; Lung Neoplasms; Male; Middle Aged; Nausea; Pyrroles; Radiotherapy; Sunitinib; Thyroid Cancer, Papillary; Thyroid Neoplasms | 2016 |
A Prospective Multicenter Trial of the Efficacy and Tolerability of Neoadjuvant Sunitinib for Inoperable Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Fatigue; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Nausea; Neoadjuvant Therapy; Prospective Studies; Pyrroles; Quality of Life; Sunitinib; Surveys and Questionnaires; Treatment Outcome | 2016 |
Maintenance Sunitinib following Initial Platinum-Based Combination Chemotherapy in Advanced-Stage IIIB/IV Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study-CALGB 30607 (Alliance).
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Double-Blind Method; Drug Eruptions; Fatigue; Female; Humans; Hypertension; Indoles; Intention to Treat Analysis; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Mucositis; Neoplasm Staging; Neutropenia; Platinum Compounds; Pyrroles; Quality of Life; Sunitinib; Survival Rate; Thrombocytopenia | 2017 |
Phase I trial of sunitinib malate plus interferon-alpha for patients with metastatic renal cell carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Fatigue; Female; Humans; Indoles; Interferon-alpha; Kidney Neoplasms; Male; Middle Aged; Neutropenia; Pyrroles; Sunitinib; Thrombocytopenia; Treatment Outcome | 2009 |
A phase II study of sunitinib in patients with recurrent and/or metastatic non-nasopharyngeal head and neck cancer.
Topics: Aged; Angiogenesis Inhibitors; Anorexia; Area Under Curve; Carcinoma, Squamous Cell; Drug Administration Schedule; Fatigue; Female; Head and Neck Neoplasms; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Immunohistochemistry; Indoles; Male; Metabolic Clearance Rate; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Pyrroles; Sunitinib; Survival Analysis; Thrombocytopenia; Treatment Outcome; Vascular Endothelial Growth Factor A | 2010 |
The efficacy and safety of sunitinib in korean patients with advanced renal cell carcinoma: high incidence of toxicity leads to frequent dose reduction.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Asian People; Carcinoma, Renal Cell; Dose-Response Relationship, Drug; Fatigue; Female; Follow-Up Studies; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Pyrroles; Republic of Korea; Sunitinib; Thrombocytopenia; Treatment Outcome | 2010 |
A phase I study of sunitinib plus capecitabine in patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Capecitabine; Deoxycytidine; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Female; Fluorouracil; Humans; Indoles; Male; Metabolic Clearance Rate; Middle Aged; Nausea; Neoplasms; Pyrroles; Sunitinib; Treatment Outcome; Vomiting; Young Adult | 2010 |
Clinical efficacy and safety of sunitinib after imatinib failure in Japanese patients with gastrointestinal stromal tumor.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Drug Administration Schedule; Drug Resistance, Neoplasm; Fatigue; Female; Gastrointestinal Stromal Tumors; Humans; Hyperammonemia; Imatinib Mesylate; Indoles; Japan; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; Middle Aged; Piperazines; Portography; Pyrimidines; Pyrroles; Remission Induction; Retrospective Studies; Sunitinib; Tomography, X-Ray Computed; Treatment Failure; Treatment Outcome | 2011 |
Phase I pharmacokinetic and pharmacodynamic study of SJG-136, a novel DNA sequence selective minor groove cross-linking agent, in advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Benzodiazepinones; Dexamethasone; Dyspnea; Edema; Fatigue; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pyrroles | 2011 |
Experience in the use of sunitinib given as a single agent in metastatic chemoresistant and castration-resistant prostate cancer patients.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Anemia; Angiogenesis Inhibitors; Castration; Diarrhea; Drug Resistance, Neoplasm; Fatigue; Hand-Foot Syndrome; Humans; Indoles; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Pyrroles; Sunitinib; Thrombocytopenia; Treatment Outcome | 2011 |
A phase I study of sunitinib combined with modified FOLFOX6 in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Female; Fluorouracil; Humans; Indoles; Leucovorin; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Pyrroles; Sunitinib; Thrombocytopenia; Treatment Outcome | 2012 |
Sorafenib or sunitinib as postoperative adjuvant therapy for Chinese patients with locally advanced clear cell renal cell carcinoma at high risk for disease recurrence.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Diarrhea; Disease-Free Survival; Fatigue; Female; Follow-Up Studies; Hand-Foot Syndrome; Humans; Indoles; Kidney; Kidney Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Postoperative Period; Prospective Studies; Pyrroles; Risk Factors; Sorafenib; Sunitinib; Treatment Outcome | 2013 |
Phase II open-label study of sunitinib in patients with advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Diarrhea; Disease-Free Survival; Fatigue; Female; Humans; Indoles; Middle Aged; Nausea; Pyrroles; Sunitinib; Thrombocytopenia; Treatment Outcome | 2012 |
Sunitinib in advanced metastatic non-clear cell renal cell carcinoma: a single institution retrospective study.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Drug Administration Schedule; Fatigue; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Retrospective Studies; Sunitinib; Treatment Outcome | 2012 |
Fluorouracil, leucovorin, and irinotecan plus either sunitinib or placebo in metastatic colorectal cancer: a randomized, phase III trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Double-Blind Method; Drug Administration Schedule; Fatigue; Female; Fluorouracil; Humans; Indoles; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Pyrroles; Sunitinib; Thrombocytopenia; Treatment Outcome | 2013 |
Results of a Phase I dose-escalating study of the antiangiogenic agent, SU5416, in patients with advanced malignancies.
Topics: Adult; Aged; Angiogenesis Inhibitors; Combined Modality Therapy; Endothelial Growth Factors; Fatigue; Female; Fibroblast Growth Factor 2; Headache; Humans; Indoles; Intercellular Signaling Peptides and Proteins; Lymphokines; Male; Middle Aged; Molecular Structure; Nausea; Neoplasms; Pyrroles; Salvage Therapy; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors; Vomiting | 2002 |
A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period.
Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Blood Pressure; Dose-Response Relationship, Drug; Fatigue; Female; Follow-Up Studies; Heart Rate; Humans; Indoles; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasms; Pancreas; Pyrroles; Sunitinib; Tomography, X-Ray Computed; Treatment Failure | 2008 |
Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Cause of Death; Cisplatin; Disease Progression; Drug Administration Schedule; Fatigue; Female; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Recurrence, Local; Neoplasm Staging; Pain; Protein-Tyrosine Kinases; Pyrroles; Remission Induction; Stomatitis; Sunitinib; Treatment Outcome | 2008 |
Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.
Topics: Administration, Oral; Adult; Aged; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Bridged-Ring Compounds; Carcinoma; Drug Administration Schedule; Fatigue; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Indoles; Middle Aged; Protein-Tyrosine Kinases; Pyrroles; Sunitinib; Survival Rate; Taxoids | 2008 |
21 other study(ies) available for pyrroles and Fatigue
| Article | Year |
|---|---|
Significance of Age in Japanese Patients Receiving Sunitinib as First-line Systemic Therapy for Metastatic Renal Cell Carcinoma: Comparative Assessment of Efficacy and Safety between Patients Aged <75 and ≥75 Years.
Topics: Aged; Aged, 80 and over; Aging; Antineoplastic Agents; Asian People; Carcinoma, Renal Cell; Disease-Free Survival; Fatigue; Female; Humans; Indoles; Japan; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pyrroles; Retrospective Studies; Sunitinib; Thrombocytopenia; Treatment Outcome | 2018 |
Mystery case: a 63-year-old man with progressive proximal pain and weakness.
Topics: Atorvastatin; Blood Sedimentation; C-Reactive Protein; Creatine Kinase; Diabetes Mellitus, Type 2; Disease Progression; Electromyography; Fatigue; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Muscle Weakness; Neuromuscular Junction Diseases; Pain; Pyrroles; Shoulder Pain; Tomography, X-Ray Computed | 2014 |
A 2 weeks on and 1 week off schedule of sunitinib is associated with decreased toxicity in metastatic renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Drug Administration Schedule; Fatigue; Female; Hand-Foot Syndrome; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pyrroles; Retrospective Studies; Sunitinib; Treatment Outcome | 2014 |
Fatigue in patients with advanced renal cell carcinoma receiving sunitinib on an intermittent versus continuous dosing schedule in a randomized phase II trial.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Drug Administration Schedule; Fatigue; Humans; Indoles; Kidney Neoplasms; Neoplasm Staging; Pyrroles; Randomized Controlled Trials as Topic; Self Report; Sunitinib; Treatment Outcome | 2014 |
Practical management of sunitinib toxicities in the treatment of pancreatic neuroendocrine tumors.
Topics: Antineoplastic Agents; Cardiovascular Diseases; Drug Administration Schedule; Fatigue; Hand-Foot Syndrome; Humans; Indoles; Neuroendocrine Tumors; Neutropenia; Pancreatic Neoplasms; Pyrroles; Stomatitis; Sunitinib; Thyroid Diseases | 2014 |
Long-term Safety of Sunitinib in Metastatic Renal Cell Carcinoma.
Topics: Anorexia; Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Diarrhea; Dysgeusia; Dyspepsia; Fatigue; Female; Humans; Hypertension; Hypothyroidism; Indoles; Kidney Neoplasms; Male; Mucositis; Nausea; Pyrroles; Stomatitis; Sunitinib; Time Factors | 2016 |
Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Renal Cell; Disease-Free Survival; Fatigue; Female; Hand-Foot Syndrome; Humans; Hypertension; Indoles; Kidney Neoplasms; Male; Middle Aged; Neutropenia; Pyrroles; Sunitinib; Survival Rate; Young Adult | 2015 |
Risk factors and model for predicting toxicity-related treatment discontinuation in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy: Results from the International Metastatic Renal Cell Carcin
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Axitinib; Bevacizumab; Carcinoma, Renal Cell; Databases, Factual; Diarrhea; Drug Administration Schedule; Fatigue; Female; Hand-Foot Syndrome; Humans; Imidazoles; Indazoles; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Models, Statistical; Molecular Targeted Therapy; Mucositis; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Pyrimidines; Pyrroles; Retrospective Studies; Risk Assessment; Risk Factors; Sorafenib; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factor A | 2016 |
Efficacy and safety of sorafenib versus sunitinib as first-line treatment in patients with metastatic renal cell carcinoma: largest single-center retrospective analysis.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Diarrhea; Disease-Free Survival; Fatigue; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome | 2016 |
Adverse reactions in mRCC patients documented in routine practice by German office-based oncologists and uro-oncologists.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Renal Cell; Diarrhea; Documentation; Fatigue; Female; Germany; Humans; Indoles; Interferons; Kidney Neoplasms; Male; Medical Oncology; Middle Aged; Nausea; Niacinamide; Phenylurea Compounds; Prospective Studies; Pyrroles; Registries; Sirolimus; Sorafenib; Stomatitis; Sunitinib | 2017 |
Sunitinib in metastatic renal cell carcinoma (mRCC): a developing country experience. Do our patients behave differently than the Western patients?
Topics: Adult; Aged; Aged, 80 and over; Anorexia; Antineoplastic Agents; Carcinoma, Renal Cell; Developing Countries; Disease-Free Survival; Fatigue; Female; Follow-Up Studies; Hand-Foot Syndrome; Humans; India; Indoles; Kidney Neoplasms; Male; Middle Aged; Mucositis; Niacinamide; Phenylurea Compounds; Pigmentation Disorders; Prospective Studies; Pyrroles; Response Evaluation Criteria in Solid Tumors; Sirolimus; Sorafenib; Sunitinib; Survival Rate; White People; Young Adult | 2016 |
Analysis of haematological changes in tofacitinib-treated patients with rheumatoid arthritis across phase 3 and long-term extension studies.
Topics: Adult; Aged; Arthritis, Rheumatoid; Blood Sedimentation; C-Reactive Protein; Cell Count; Clinical Trials, Phase III as Topic; Fatigue; Female; Hemoglobins; Humans; Longitudinal Studies; Lymphocyte Count; Male; Middle Aged; Neutrophils; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome | 2017 |
Optimizing the use of sunitinib in metastatic renal cell carcinoma: an update from clinical practice.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Asthenia; Carcinoma, Renal Cell; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Tolerance; Fatigue; Humans; Indoles; Kidney Neoplasms; Medical History Taking; Neoplasm Metastasis; Proportional Hazards Models; Pyrroles; Sunitinib | 2010 |
Safety and treatment patterns of multikinase inhibitors in patients with metastatic renal cell carcinoma at a tertiary oncology center in Italy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma; Fatigue; Female; Humans; Indoles; Italy; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Oncology Service, Hospital; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome | 2011 |
Efficacy and safety of vascular endothelial growth factor receptor tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma and poor risk features.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Drug Administration Schedule; Fatigue; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Retrospective Studies; Sorafenib; Sulfonamides; Sunitinib; Survival Analysis; Thrombocytopenia; Treatment Outcome; Young Adult | 2012 |
C-reactive protein as a prognostic marker for advanced renal cell carcinoma treated with sunitinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; C-Reactive Protein; Carcinoma, Renal Cell; Disease-Free Survival; Fatigue; Female; Hand-Foot Syndrome; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Leukopenia; Logistic Models; Male; Middle Aged; Multivariate Analysis; Predictive Value of Tests; Pyrroles; Retrospective Studies; Sunitinib; Taste Disorders | 2012 |
Potential role of licofelone, minocycline and their combination against chronic fatigue stress induced behavioral, biochemical and mitochondrial alterations in mice.
Topics: Animals; Chronic Disease; Drug Therapy, Combination; Fatigue; Glutathione; Lipid Peroxidation; Male; Maze Learning; Mice; Minocycline; Mitochondria; Motor Activity; Pyrroles; Stress, Psychological | 2012 |
Facilitation of cardiac vagal activity by CRF-R1 antagonists during swim stress in rats.
Topics: Animals; Bradycardia; Cholinergic Antagonists; Corticotropin-Releasing Hormone; Death, Sudden, Cardiac; Disease Models, Animal; Exercise Tolerance; Fatigue; Heart Rate; Hypothalamo-Hypophyseal System; Hypothermia, Induced; Male; Mifepristone; Peptide Fragments; Psychomotor Agitation; Pyrimidines; Pyrroles; Rats; Rats, Sprague-Dawley; Receptors, Corticotropin-Releasing Hormone; Stress, Psychological; Swimming; Vagus Nerve; Vagus Nerve Diseases | 2006 |
Fatigue with sunitinib-induced hypothyroidism.
Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; Fatigue; Humans; Hypothyroidism; Indoles; Kidney Neoplasms; Pyrroles; Sunitinib | 2007 |
Sunitinib and hypothyroidism.
Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; Fatigue; Humans; Hypothyroidism; Indoles; Interferon-alpha; Kidney Neoplasms; Pyrroles; Sunitinib | 2007 |
[No relationship between so-called 'haemopyrrollactamuria' and fatigue in secondary-school students].
Topics: Adolescent; Cross-Sectional Studies; Fatigue; Female; Humans; Male; Pyrroles; Surveys and Questionnaires; Urinalysis | 2007 |